Loiasis Clinical Trial - Spontaneous Antigenemia in Loiasis

Status Active, not recruiting

Clinical Trial Summary

This prospective study will enroll and follow 60 loiasis patients with high worm burden to monitor the spontaneous release of filarial antigen in peripheral blood. This study will define the cross-reactive antigen profile of persons with spontaneous loiasis antigenemia, and determine whether it varies with time.

Clinical Trial Description

Global efforts to eradicate lymphatic filariasis (LF) depend on rapid diagnostic tests (RDTs) that detect Wuchereria bancrofti circulating filarial antigen but these tests are unreliable in African nations where Loa loa is co-endemic because they yield false-positive results in some individuals with loiasis. The goals of this project are to define the cross-reactive antigen profile of persons with spontaneous antigenemia, how it varies over time, and to determine which L. loa antigens in cross-reactive sera best distinguish loiasis cross-reactivity from LF.

This prospective study will prospectively enroll 50 adults who presented with cross-reactive antigenemia at screening and 10 negative controls. Participants will followed for one year and tested every three months for persistence of antigenemia. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04258670
Study type	Observational [Patient Registry]
Source	Washington University School of Medicine
Contact
Status	Active, not recruiting
Phase
Start date	January 23, 2020
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00375583` - Effect of Albendazole Dose on Clearance of Filarial Worms	Phase 2
Completed	`NCT03664063` - PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )	Phase 2
Recruiting	`NCT04844905` - Adjunctive Ivermectin Mass Drug Administration for Malaria Control	Phase 3
Completed	`NCT01975441` - Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa	Phase 2
Completed	`NCT01629771` - Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India	N/A
Completed	`NCT01905423` - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Completed	`NCT02784743` - Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali	Phase 4
Completed	`NCT03036059` - Twice Yearly Treatment for the Control of LF	Phase 4
Completed	`NCT01905436` - Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Completed	`NCT02509481` - Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study	Phase 2/Phase 3
Completed	`NCT03268252` - Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
Completed	`NCT02927496` - A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali	Phase 3
Completed	`NCT02899936` - Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis	N/A
Completed	`NCT00511004` - Effect of Albendazole Dose on Treatment of Lymphatic Filariasis	Phase 2
Completed	`NCT02974049` - Lymphatic Filariasis (LF) in Ivory Coast	N/A
Terminated	`NCT01213576` - Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi	N/A
Completed	`NCT02929121` - A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India	Phase 3
Completed	`NCT00339417` - Effect of Albendazole Dose on Clearance of Filarial Worms	Phase 2
Withdrawn	`NCT01903057` - Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis	Phase 4
Completed	`NCT02032043` - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)